Aurora Products, Inc. Announces Voluntarily Recall of Aurora Natural Brand and Certain Private Label Branded Raw Macadamia Nuts Due to Possible Health Risk

Aurora Products, Inc. is conducting a voluntary recall of RAW MACADAMIA NUTS packaged under the Aurora brand label and various Store brand labels. Products are being recalled because they have the potential to contain Salmonella which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain.

CONSUMER ALERT: Undeclared Peanuts in "Cumin Powder"

New York State Agriculture Commissioner Richard A. Ball today alerted consumers to undeclared peanuts in Crown Food International “Cummin Powder,” packaged and distributed by Crown Food International LLC, located at 45-30 38th St, Long Island City, NY 11101. People who have severe sensitivity to peanuts may run the risk of serious or life-threatening reactions if they consume this product.

FDA approves spinal cord stimulation system that treats pain without tingling sensation

Today the U.S. Food and Drug Administration approved the Senza spinal cord stimulation (SCS) system (Senza System) as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain and leg pain. The Senza System can reduce pain without producing a tingling sensation called paresthesia by providing high frequency stimulation (at 10 KHz) and low stimulation amplitudes.

FDA approves spinal cord stimulation system that treats pain without tingling sensation

Today the U.S. Food and Drug Administration approved the Senza spinal cord stimulation (SCS) system (Senza System) as an aid in the management of chronic intractable pain of the trunk and/or limbs, including pain associated with failed back surgery syndrome, low back pain and leg pain. The Senza System can reduce pain without producing a tingling sensation called paresthesia by providing high frequency stimulation (at 10 KHz) and low stimulation amplitudes.

FDA approves additional antibacterial treatment for plague

The U.S. Food and Drug Administration today approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients.

FDA approves additional antibacterial treatment for plague

The U.S. Food and Drug Administration today approved Avelox (moxifloxacin) to treat patients with plague, a rare and potentially fatal bacterial infection. The agency approval for plague includes use of the drug for the treatment of pneumonic plague (infection of the lungs), and septicemic plague (infection of the blood). Avelox is also approved for prevention of plague in adult patients.